Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|EXEL||Community voting in process|
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?